CN109862918A - 包括细菌叶绿素衍生物的用于治疗癌症的联合疗法 - Google Patents

包括细菌叶绿素衍生物的用于治疗癌症的联合疗法 Download PDF

Info

Publication number
CN109862918A
CN109862918A CN201780035366.4A CN201780035366A CN109862918A CN 109862918 A CN109862918 A CN 109862918A CN 201780035366 A CN201780035366 A CN 201780035366A CN 109862918 A CN109862918 A CN 109862918A
Authority
CN
China
Prior art keywords
bchl
mdsc
agent
pdt
vtp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780035366.4A
Other languages
English (en)
Chinese (zh)
Inventor
A·舍茨
Y·所罗门
L·阿格美
R·哈姆瑞
D·普瑞斯
K·金姆
J·科尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Memorial Sloan Kettering Cancer Center
Original Assignee
Yeda Research and Development Co Ltd
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd, Memorial Sloan Kettering Cancer Center filed Critical Yeda Research and Development Co Ltd
Priority to CN202410235521.9A priority Critical patent/CN118304400A/zh
Publication of CN109862918A publication Critical patent/CN109862918A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780035366.4A 2016-04-10 2017-04-10 包括细菌叶绿素衍生物的用于治疗癌症的联合疗法 Pending CN109862918A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410235521.9A CN118304400A (zh) 2016-04-10 2017-04-10 包括细菌叶绿素衍生物的用于治疗癌症的联合疗法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662320549P 2016-04-10 2016-04-10
US62/320,549 2016-04-10
PCT/IL2017/050440 WO2017179053A1 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410235521.9A Division CN118304400A (zh) 2016-04-10 2017-04-10 包括细菌叶绿素衍生物的用于治疗癌症的联合疗法

Publications (1)

Publication Number Publication Date
CN109862918A true CN109862918A (zh) 2019-06-07

Family

ID=58794130

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780035366.4A Pending CN109862918A (zh) 2016-04-10 2017-04-10 包括细菌叶绿素衍生物的用于治疗癌症的联合疗法
CN202410235521.9A Pending CN118304400A (zh) 2016-04-10 2017-04-10 包括细菌叶绿素衍生物的用于治疗癌症的联合疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410235521.9A Pending CN118304400A (zh) 2016-04-10 2017-04-10 包括细菌叶绿素衍生物的用于治疗癌症的联合疗法

Country Status (14)

Country Link
US (2) US11278555B2 (https=)
EP (1) EP3442582A1 (https=)
JP (2) JP2019510807A (https=)
KR (2) KR20220139445A (https=)
CN (2) CN109862918A (https=)
AU (2) AU2017250732B2 (https=)
BR (1) BR112018070847A2 (https=)
CA (1) CA3020067A1 (https=)
IL (1) IL262191B2 (https=)
MX (2) MX390751B (https=)
RU (2) RU2021110230A (https=)
SG (1) SG11201808849TA (https=)
WO (1) WO2017179053A1 (https=)
ZA (1) ZA201807187B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107240B2 (en) 2014-04-04 2018-10-23 Dayco Ip Holdings, Llc Check valves and Venturi devices having the same
JP6609626B2 (ja) 2014-05-30 2019-11-20 デイコ アイピー ホールディングス，エルエルシー エジェクタ、空圧式制御バルブ及び選択的なアスピレータを有する真空発生システム
EP3723785A1 (en) * 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
KR20220100546A (ko) * 2021-01-08 2022-07-15 가톨릭대학교 산학협력단 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023378A1 (en) * 2006-08-23 2008-02-28 Yeda Research And Development Co. Ltd Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
CN102002048A (zh) * 2002-11-17 2011-04-06 耶达研究及发展有限公司 水溶性阴离子型细菌叶绿素衍生物及其用途
US20120323163A1 (en) * 2011-05-18 2012-12-20 National Taiwan University Methods of using dual-effect liposome in therapy
WO2014141289A1 (en) * 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1137411B1 (en) 1998-12-09 2006-12-06 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Palladium-substituted bacteriochlorophyll derivatives and use thereof
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
ES2627377T3 (es) 2008-10-23 2017-07-27 Steba Biotech S.A. Peptidomiméticos que contienen RGD y sus usos
AU2012212323A1 (en) * 2011-02-01 2013-09-12 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102002048A (zh) * 2002-11-17 2011-04-06 耶达研究及发展有限公司 水溶性阴离子型细菌叶绿素衍生物及其用途
WO2008023378A1 (en) * 2006-08-23 2008-02-28 Yeda Research And Development Co. Ltd Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
US20120323163A1 (en) * 2011-05-18 2012-12-20 National Taiwan University Methods of using dual-effect liposome in therapy
WO2014141289A1 (en) * 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BRIGGS ET AL.: ""THE EFFECT OF COMBINATION TREATMENT WITH GEMCITABINE AND THE EGFR-RECEPTOR TYROSINE KINASE IYHIBITOR IRESSA WITH PHOTODYNAMIC THERAPY IN BLADDER CANCER"", 《EUROPEAN UROLOGY SUPPLEMENTS》 *
CRESCENZI ET AL.: ""Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phaserelated activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)"", 《MOL CANCER THER》 *
KELLEHER ET AL.: "Combined hyperthermia and chlorophyll-based photodynamic therapy: tumour growth and metabolic microenvironment", 《BRITISH JOURNAL OF CANCER》 *
MIN ET AL.: "Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer", 《THE KOREAN JOURNAL OF INTERNAL MEDICINE》 *
PREISE ET AL.: "Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity", 《CANCER IMMUNOL IMMUNOTHER》 *
SUN ET AL.: "Synergistic Effects of Photodynamic Therapy With HPPH and Gemcitabine in Pancreatic Cancer Cell Lines", 《LASERS IN SURGERY AND MEDICINE》 *
XIE ET AL.: ""Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo"", 《WORLD J GASTROENTEROL》 *
YOSHIKAZU ET AL.: ""Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma"", 《JOURNAL OF SURGICAL RESEARCH》 *

Also Published As

Publication number Publication date
CA3020067A1 (en) 2017-10-19
IL262191B2 (en) 2025-01-01
AU2023200591A1 (en) 2023-03-09
JP2019510807A (ja) 2019-04-18
CN118304400A (zh) 2024-07-09
SG11201808849TA (en) 2018-11-29
RU2018139523A3 (https=) 2020-07-07
KR20220139445A (ko) 2022-10-14
IL262191B1 (en) 2024-09-01
JP2022031823A (ja) 2022-02-22
BR112018070847A2 (pt) 2019-02-05
US11278555B2 (en) 2022-03-22
IL262191A (en) 2018-11-29
WO2017179053A1 (en) 2017-10-19
AU2017250732A1 (en) 2018-11-15
EP3442582A1 (en) 2019-02-20
US20220202838A1 (en) 2022-06-30
AU2017250732B2 (en) 2022-11-10
MX390751B (es) 2025-03-21
RU2747258C2 (ru) 2021-04-29
MX2018012392A (es) 2019-08-21
US20190125769A1 (en) 2019-05-02
RU2018139523A (ru) 2020-05-15
ZA201807187B (en) 2020-01-29
RU2021110230A (ru) 2021-05-26
KR20190008206A (ko) 2019-01-23
MX2022003190A (es) 2022-04-11

Similar Documents

Publication Publication Date Title
US20220202838A1 (en) Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative
Al Jarroudi et al. Anti-programmed cell death protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: a report of three cases
US20220313822A1 (en) Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antibody-phthalocyanine dye conjugate and anti-pd1 antibody
AU2006312013B2 (en) Concurrent chemotherapy and immunotherapy
CN107109363A (zh) 增强对异常细胞杀伤力的方法和药物组合物
Xiong et al. Near-infrared-II Ag2S quantum dot probes targeting podoplanin enhance immunotherapy in oral squamous cell carcinoma
CN108601836A (zh) 用于膀胱癌的新辅助疗法
CA2358754A1 (en) Synergistic tumorcidal response induced by histamine
Kim et al. Abscopal resolution of a hepatic metastasis in a patient with metastatic cholangiocarcinoma following radical stereotactic body radiotherapy to a synchronous early stage non-small cell lung cancer
De Silva et al. Photodynamic priming with red light triggers adaptive immune responses in a pancreatic cancer mouse model
Brown et al. SPECT/CT lymphoscintigraphy of heterotopic cardiac grafts reveals novel sites of lymphatic drainage and T cell priming
US20220296712A1 (en) Methods for treatment using phthalocyanine dye-targeting molecule conjugates
Wang et al. Enhancing brain entry and therapeutic activity of chimeric antigen receptor T cells with intra-arterial NEO100 in a mouse model of CNS lymphoma
Khanna et al. Does bacillus Calmette-Guérin immunotherapy accelerate growth and cause metastatic spread of second primary malignancy?
Huang et al. A versatile nanoplatform for enhancing the therapeutic efficacy against low-immunogenic TNBC by inducing immunogenic cell death and MHC-I upregulation
Li et al. Fluence rate differences in photodynamic therapy efficacy and activation of immune checkpoints of murine colorectal cancer
Kim et al. Evaluating an immunotherapeutic approach to photodynamic therapy for glioblastoma
Hamri Targeting the microenvironment of 4T1 tumors using RGD-conjugated bacteriochlorophylls as a theranostic tool
US20200030375A1 (en) Therapy and methods of introducing immature dendritic cells and/or cytoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors
Halldórsdóttir Fantastic T cells and how to track them: Methods for tracking adoptively transferred T cells and enhancing efficacy of cellular therapies
Cell et al. Cancers 2020, 12, 545; doi: 10.3390/cancers12030545 www. mdpi. com/journal/cancers
WO2020227279A1 (en) Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors
US20070166313A1 (en) Administration of gamma globulins to treat cancer
Shams Split-dose photodynamic therapy: Optimizing cures while preventing disseminated tumors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190607